NRSN

Business Context and Reporting Period

Company: NeuroSense Therapeutics Ltd. (NRSN)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: NeuroSense is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases, primarily Amyotrophic Lateral Sclerosis (ALS). Its lead product candidate, PrimeC, is a fixed-dose combination of ciprofloxacin and celecoxib. The company has no approved products and has not generated any revenue to date.

Key Financial Metrics

Note: The filing text does not provide specific data for Q4 2025 in isolation; the figures above represent the full fiscal year 2025.

Material Changes vs. Prior Period

• Net Loss Increase: Net loss increased by approximately 8.9% year-over-year, driven primarily by a 141% increase in share-based compensation expenses within General and Administrative (G&A) costs.
• Operating Cash Flow: Net cash used in operating activities decreased by $2.5 million compared to 2024, attributed to the conclusion of specific clinical study activities at the end of 2024.
• Liquidity Decline: Cash and cash equivalents dropped significantly from $3.4 million in 2024 to $0.2 million in 2025, raising substantial doubt about the company's ability to continue as a going concern without additional financing.
• Capital Structure: The company raised approximately $4.4 million through financing activities in 2025, including sales under an At-The-Market (ATM) agreement and a Standby Equity Purchase Agreement (SEPA).

Guidance, Outlook, and Risks

Outlook and Guidance

• Going Concern: The company explicitly states that its current cash resources are insufficient to fund operations for at least 12 months from the date of the report. Future operations depend on successful equity or debt financing.
• Clinical Development: The company received FDA clearance in November 2025 to initiate a pivotal Phase 3 clinical trial for PrimeC in ALS. Enrollment is targeted for 2026 pending resource securing.
• Regulatory Strategy: The company is pursuing a 505(b)(2) regulatory pathway in the U.S. and exploring early commercialization approval in Canada (NOC/c pathway), with a potential submission anticipated in mid-to-late 2026.
• Partnerships: A binding term sheet with a global pharmaceutical company entered in December 2024 was concluded in March 2026 due to material organizational changes at the counterparty.

Risks and Contingencies

• Geopolitical Instability: Operations are based in Israel. The filing highlights significant risks related to ongoing regional conflicts (Hamas, Hezbollah, Iran), including potential mobilization of employees, supply chain disruptions, and economic instability.
• Capital Requirements: Failure to secure additional capital could force the company to delay, limit, or terminate product development and clinical trials.
• Regulatory Uncertainty: There is no assurance that the FDA will accept the proposed 505(b)(2) pathway or that the pivotal trial will be sufficient for approval.
• Nasdaq Compliance: The company is subject to Nasdaq listing requirements regarding minimum bid price and market value of listed securities, with a risk of delisting if these are not maintained.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $0.2 million cash balance against the projected costs of the upcoming Phase 3 trial and general operations.
• Financing Progress: Confirm the status of ongoing fundraising efforts under the ATM and SEPA agreements to ensure continuity of operations.
• Phase 3 Trial Initiation: Monitor the timeline for the first patient enrollment in the pivotal Phase 3 trial, which is contingent on securing strategic resources.
• Geopolitical Impact: Assess the actual impact of the security situation in Israel on employee availability, clinical trial sites, and supply chain logistics.
• Partnership Status: Evaluate the company's pipeline for new strategic partnerships following the termination of the December 2024 term sheet.